2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis

Tate, Jacqueline E.; Burton, Anthony; Boschi-Pinto, Cynthia; Steele, A. Duncan; Duque, Jazmin; Parashar, Umesh D.

doi:10.1016/s1473-3099(11)70253-5

Cited by 1,146 publications

(939 citation statements)

References 24 publications

Supporting

Mentioning

817

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3] In 2013, rotavirus was responsible for 37% of all deaths caused by diarrheal disease in children younger than 5 y of age, leading to 215,000 deaths globally. 3 While rotavirus is ubiquitous, the greatest disease burden and over 90% of related deaths occur in lowincome and low-middle-income countries.…”

Section: Introductionmentioning

confidence: 99%

Options for improving effectiveness of rotavirus vaccines in developing countries

Tissera

Cowley

Bogdanovic-Sakran

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90%. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60% in developing countries, but have been proven life-saving. Bridging this "efficacy gap" offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.

show abstract

Section: Introductionmentioning

confidence: 99%

Options for improving effectiveness of rotavirus vaccines in developing countries

Tissera

Cowley

Bogdanovic-Sakran

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…The main symptoms of rotavirus-related gastroenteritis (RVGE) are watery, non-bloody diarrhea with vomiting and fever lasting from 4 to 7 days. According to international estimates, 453 000 deaths in children under the age of 5 every year worldwide are due to RV infection (2). In Germany, before vaccination was introduced, RVGE was the commonest notifiable disease in under 5-year-olds; the highest annual incidence was seen in children under the age of 2 (1850 / 100 000) (3).…”

mentioning

confidence: 99%

Risk of Intussusception After Rotavirus Vaccination

Koch¹,

Harder²,

Kries³

et al. 2017

Deutsches Ärzteblatt International

View full text Add to dashboard Cite

SUMMARYBackground: In 2013, the German Standing Committee on Vaccination (Stän-dige Impfkommission, STIKO) recommended rotavirus (RV) vaccination for all infants while stating that this mildly increased the risk of intussusception, a potentially life-threatening event. Since this recommendation was issued, multiple observational studies on this topic designed as self-controlled case series (SCCS) have been published. The SCCS design is particularly suitable for the study of rare adverse effects of medications.

show abstract

mentioning

confidence: 99%

“…Rotavirus, the single most important cause of severe childhood diarrhea globally, accounts for about onethird of all deaths attributable to diarrhea, and 5% of all childhood deaths [3]. The vast majority of deaths from rotavirus occur in low-income countries, with more than half occurring in Africa [3]. Rotavirus infections also put considerable burden on healthcare systems, accounting for 40% of all gastroenteritis hospitalizations for children aged <5 years worldwide, including in African countries [4].…”

mentioning

confidence: 99%

Impact of Rotavirus Vaccination on Hospitalizations and Deaths From Childhood Gastroenteritis in Botswana

et al. 2016

View full text Add to dashboard Cite

Background. A monovalent human rotavirus vaccine (RV1) was introduced in Botswana in July 2012. We assessed the impact of RV1 vaccination on childhood gastroenteritis-related hospitalizations and deaths in 2013 and 2014.Methods. We obtained data from registers of 4 hospitals in Botswana on hospitalizations and deaths from gastroenteritis, regardless of cause, among children <5 years of age. Gastroenteritis hospitalizations and deaths during the prevaccine period (January 2009-December 2012) were compared to the postvaccine period (January 2013-December 2014). Vaccine coverage was estimated from data collected through a concurrent vaccine effectiveness study at the same hospitals.Results. By December 2014, coverage with ≥1 dose of RV1 was an estimated 90% among infants <1 year of age and 76% among children 12-23 months of age. In the prevaccine period, the annual median number of gastroenteritis-related hospitalizations in children <5 years of age was 1212, and of gastroenteritis-related deaths in children <2 years of age was 77. In the postvaccine period, gastroenteritis-related hospitalizations decreased by 23% (95% confidence interval [CI], 16%-29%) to 937, and gastroenteritis-related deaths decreased by 22% (95% CI, −9% to 44%) to 60. Declines were most prominent during the rotavirus season (May-October) and among infants <1 year of age, with reductions of 43% (95% CI, 34%-51%) in gastroenteritis hospitalizations and 48% (95% CI, 11%-69%) in gastroenteritis deaths.Conclusions. Following introduction of RV1 into the national immunization program, significant declines in hospitalizations and deaths from gastroenteritis were observed among children in Botswana, suggestive of the beneficial public health impact of rotavirus vaccination.

show abstract

2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis

Abstract: Introduction of effective and available rotavirus vaccines could substantially affect worldwide deaths attributable to diarrhoea. Our new estimates can be used to advocate for rotavirus vaccine introduction and to monitor the effect of vaccination on mortality once introduced.

Cited by 1,146 publications

References 24 publications

Options for improving effectiveness of rotavirus vaccines in developing countries

Options for improving effectiveness of rotavirus vaccines in developing countries

Risk of Intussusception After Rotavirus Vaccination

Impact of Rotavirus Vaccination on Hospitalizations and Deaths From Childhood Gastroenteritis in Botswana

Contact Info

Product

Resources

About